Persons with renal disease (calculi or insufficiency) ‐ Vitamin D (D2, D3 or 25(OH)D) plus calcium (1 year estimate) · post‐menopausal women and older people at risk of osteoporotic fractures
Vitamin D [D2, D3 or 25(OH)D] plus calcium leads to higher persons with renal disease (calculi or insufficiency) ‐ Vitamin D… compared with control or placebo (high certainty).
1 finding from 1 review
Deaths ‐ Vitamin D (D2, D3, 25(OH)D) plus calcium (1 year estimate) · post‐menopausal women and older people at risk of osteoporotic fractures
Vitamin D [D2, D3 or 25(OH)D] plus calcium showed no clear difference in deaths ‐ Vitamin D (D2, D3, 25(OH)D) plus calcium (1 year estimate) compared with control or placebo (high certainty).
1 finding from 1 review
Serum phosphorus · people with CKD‐MBD
1 finding from 1 review
Alkaline phosphatase · people with CKD‐MBD
1 finding from 1 review
All‐cause mortality · people with CKD‐MBD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cardiovascular events · people with CKD‐MBD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Fracture · people with CKD‐MBD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death or dependency at end of · people with acute ischemic stroke
Calcium antagonists showed no clear difference in death or dependency at end of compared with placebo (moderate certainty).
1 finding from 1 review
Death at the end of treatment · people with acute ischemic stroke
Calcium antagonists showed no clear difference in death at the end of treatment compared with placebo (moderate certainty).
1 finding from 1 review
Death at the end of · people with acute ischemic stroke
Calcium antagonists showed no clear difference in death at the end of compared with placebo (moderate certainty).
1 finding from 1 review
Recurrence of stroke at the end of · people with acute ischemic stroke
Calcium antagonists showed no clear difference in recurrence of stroke at the end of compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events during treatment period · people with acute ischemic stroke
Calcium antagonists showed no clear difference in adverse events during treatment period compared with placebo (moderate certainty).
1 finding from 1 review
Hypotension · people with acute ischemic stroke
Calcium antagonists showed no clear difference in hypotension during treatment period compared with placebo (moderate certainty).
1 finding from 1 review
Systolic blood pressure · people with acute ischemic stroke
Calcium antagonists showed no clear difference in mean systolic blood pressure during or at end of treatment compared with placebo (low certainty).
1 finding from 1 review
Clinical failure · Children with extensive decay involving the dental pulp in primary teeth
It is very uncertain whether calcium hydroxide cement (Dycal) changes clinical failure compared with calcium sulphate hemihydrate (DentoGen) (very low certainty).
1 finding from 1 review
Radiological failure · Children with extensive decay involving the dental pulp in primary teeth
It is very uncertain whether calcium hydroxide cement (Dycal) changes radiological failure compared with calcium sulphate hemihydrate (DentoGen) (very low certainty).
1 finding from 1 review
Total hip BMD · premenopausal women (ages 18–36 years)
1 finding from 1 review
Lumbar spine bone mineral density (BMD) · premenopausal women (ages 18–36 years)
1 finding from 1 review
Quality of life · premenopausal women (ages 18–36 years)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Vertebral fracture · premenopausal women (ages 18–36 years)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found